Publications

Recent publications from our research center

Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease
Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, Prell T, Ringer TM, Rhode H, Stevens O, Claeys KG, Couwelier G, D'Hondt A, Lamaire N, Tilkin P, Van Reijen D, Gourmaud S, Fedtke N, Heiling B, Rumpel M, Rödiger A, Gunkel A, Witte OW, Paquet C, Vandenberghe R, Grosskreutz J, Van Damme P
Neurology. 2017

Philip Van Damme and his team, in collaboration with UZ Leuven and researchers at the University of Jena, has demonstrated that measuring neurofilaments provides reliable confirmation of an ALS diagnosis. They show that pNfH (phosphorylated neurofilament heavy) in particular is sharply increased in the lumbar fluid of ALS patients, even when compared to patients presenting loss of strength symptoms due to other conditions (known as ALS mimics). This diagnostic test represents a significant step forward because valuable time is still lost at present in diagnosing ALS.

   

Inactivation of γ‐secretases leads to accumulation of substrates and non‐Alzheimer neurodegeneration
Acx H, Serneels L, Radaelli E, Muyldermans S, Vincke C, Pepermans E, Müller U, Chávez‐Gutiérrez L, De Strooper B
EMBO Mol Medicine. 2017

The De Strooper lab made knockouts of the 3 different variants of the Aph1 subunit of gamma-secretase in pyramidal neurons, and found specific neurodegeneration in the combined knockout but not the specific knockouts. These data support the possibility that different gamma-secretases can at least partially compensate for each other’s loss.

 

   

Identification and Characterisation of Nanobodies targeting the EphA4 receptor
Schoonaert L, Rué L, Roucourt B, Timmers M, Little S, Chávez Gutiérrez L, Dewilde M1 Joyce P, Curnock A, Weber P, Haustraete J, Hassanzadeh-Ghassabeh G, De Strooper B, Van Den Bosch L, Van Damme P, Lemmens R, Robberecht W
J Biol Chem. 2017

Lies Schoonaert and Laura Rué set out to generate potent and selective Nanobodies against the ligand-binding domain of the human EphA4 receptor, which plays a pivotal role in a variety of cell-cell interactions and is involved in cancer biology as well as in the pathogenesis of several neurological disorders. The team identified two Nanobodies, Nb 39 and Nb 53, that bind EphA4 with affinities in the nanomolar range.

   

Autophagy in the presynaptic compartment in health and disease
Vijayan V, Verstreken P
JCB. 2017

Evidence from research on both autophagy and synaptic function suggests that there are links between the two and that synaptic homeostasis during aging requires autophagy to regulate protein homeostasis. Vinoy Vijayan and Patrik Verstreken review exciting new work on autophagy-modulating proteins that are enriched at the synapse and highlight how these findings link autophagy to synapses and synaptic dysfunction in disease.

   

Tau association with synaptic vesicles causes presynaptic dysfunction
Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, Wang YC, Swerts J, Beyens J, Miskiewicz K, Vilain S, Dewachter I, Moechars D, De Strooper B, Spires-Jones TL, de Wit J, Verstreken P
Nature Communications. 2017

Lujia Zhou and Joe McInnes from the Verstreken lab show that pathogenic Tau binds to synaptic vesicles via its N-terminal domain and interferes with presynaptic functions. Pathological Tau mutants lacking the vesicle binding domain still localize to the presynaptic compartment but do not impair synaptic function in fly neurons. This work uncovers a presynaptic role of Tau that may be part of the early pathology in various Tauopathies and could be exploited therapeutically.

   

Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo
Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, Saftig P, Van Damme P
Human Mol Genet. 2017

Sander Beel and Philip Van Damme from the Van Den Bosch lab show that dysfunction of lysosomal enzymes such as cathepsin D can contribute to neuronal dysfunction caused by progranulin deficiency in diseases such as frontotemporal dementia.

   

Neuronal Polarity: MAP2 Shifts Secretory Vesicles into High Gear for Long-Haul Transport down the Axon
Ribeiro LF, de Wit J
Preview in Neuron. 2017

Accurate control of polarized cargo trafficking is essential for neuronal function. Luis Ribeiro and Joris de Wit wrote a comment on a paper by Gumy et al. (2017), which shows that MAP2 defines a pre-axonal filtering zone and controls axonal cargo transport by influencing the activities of distinct kinesin motors.

   

Modelling amyotrophic lateral sclerosis: progress and possibilities
Van Damme P, Robberecht W, Van Den Bosch L 
Disease Models & Mechanisms. 2017

To date, around 20 genes are associated with ALS, with the most common causes of typical ALS associated with mutations in SOD1, TARDBP, FUS and C9orf72. Advances in our understanding of the genetic basis of ALS have led to the creation of different models of this disease and Philip Van Damme, Wim Robberecht and Ludo Van Den Bosch describe the state of the field.

   

Alzheimer’s disease: where next for anti-amyloid therapies?
De Strooper B, Hardy J 
BRAIN. 2017

Guest editorial by Bart De Strooper and John Hardy in Brain on the future of anti-amyloid therapies. They make the case that systematic and open data analysis at all stages of disease investigation will be key if we want to make progress.

   

An immunoaffinity-based method for isolating ultrapure adult astrocytes based on ATP1B2 targeting by the ACSA-2 antibody
Batiuk MY, de Vin F, Duqué SI, Li C, Saito T, Saido T, Fiers M, Belgard TH, Holt MG 
JBC. 2017

The Holt lab identifies the epitope for the ACSA-2 antibody and demonstrates how the antibody can be used to isolate ultrapure astrocytes from adult brain. They suggest that ACSA-2 should be a first-choice method for astrocyte isolation and characterization.

   

Prediction and Reduction of the Aggregation of Monoclonal Antibodies
van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R. Seeliger D, Aßfalg K, Baatsen P, Compernolle G, Gils A, Studts JM, Schulz P, Garidel P, Schymkowitz J, Rousseau F 
Journal of Molecular Biology. 2017

The Switch lab on how to predict and redesign the solubility of monoclonal antibodies by introducing artificial aggregation gatekeeper residues.

   

Hallmarks of Alzheimer’s Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain
Espuny-Camacho I, Arranz AM, Fiers M, Snellinx A, Ando K, Munck S, Bonnefont J, Lambot L, Corthout N, Omodho L, Vanden Eynden E, Radaelli E, Tesseur I, Wray S, Ebneth A, Hardy J, Leroy K, Brion JP, Vanderhaeghen P, De Strooper B
Neuron. 2017

The De Strooper lab teamed up with Pierre Vanderhaeghen (ULB and visiting PI at our department) to develop a new chimeric AD model: they transplanted differentiated iPS cells into the brains of AD mice and found degeneration and major loss of human neurons without the presence of Tau tangles. This novel model opens up new ways of studying AD in a human genetic background.

[Think this work is fascinating and want to work with this model yourself? Take a look at our Careers page, the De Strooper lab is hiring!]

   

Tetraspanin 6: A novel regulator of hippocampal synaptic transmission and long term plasticity
Salas IH, Callaerts-Vegh Z, Arranz AM, Guix FX, D'Hooge R, Esteban JA, De Strooper B, Dotti CG
PLoS ONE. 2017

Tetraspanins are transmembrane proteins with important scaffold and signalling functions. Since Tetraspanin 7 plays a key role in synapse development, Isabel Salas from the De Strooper and Dotti labs explored how of Tetraspanin 6 affects synaptic function using a knock-out mouse model.

   

Cardiolipin promotes electron transport between ubiquinone and complex I to rescue PINK1 deficiency
Vos M, Geens A, Böhm C, Deaulmerie L, Swerts J, Rossi M, Craessaerts K, Leites EP, Seibler P, Rakovic A, Lohnau T, De Strooper B, Fendt SM, Morais VA, Klein C, Verstreken P
JCB. 2017

The Verstreken lab teamed up with several collaborators to show that inhibition of FASN (fatty acid synthase) rescues Parkinson's disease-associated PINK1 deficiency in flies, in mouse cells and in human cells and neurons. Lower FASN activity increases the levels of Cardiolipin (a mitochondrial inner membrane–specific lipid) which rescues PINK1 deficiency by bypassing the complex I defects. 

   

A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: the case of NPC1 deficiency
Tharkeshwar AK, Trekker J, Vermeire W, Pauwels J, Sannerud R, Priestman DA, Te Vruchte D, Vints K, Baatsen P, Decuypere JP, Lu H, Martin S, Vangheluwe P, Swinnen JV, Lagae L, Impens F, Platt FM, Gevaert K, Annaert W
Sci Rep. 2017

The lab of Wim Annaert engineered superparamagnetic iron oxide nanoparticles (SPIONs) targeting distinct subcellular compartments. They used different types of SPIONs to compare the biomolecular compositions of lysosomes and plasma membranes isolated from wild-type and Niemann-Pick disease type C1 (NPC1) deficient cells, and found disease-related alterations that were location specific. These findings demonstrate how SPIONs can be used to fingerprint sub cellular compartments and identify pathological changes at a much better resolution than in whole cells or tissues.

   

Decoding transcriptional states in cancer 
Wouters J, Kalender Atak Z, Aerts S
Curr Opin Genet Dev. 2017

New algorithms, data integration strategies, and increasing amounts of single-cell genomics data provide exciting opportunities to model dynamic regulatory states at unprecedented resolution. In this review, Jasper Wouters, Zeynep Kalender Atak and Stein Aerts give an overview of recent experimental and computational techniques using transcriptome and epigenome data that can be used to reverse engineer cancer gene networks. 

   

PLD3 gene and APP processing 
Fazzari P, Horré K, Arranz AM, Sala Frigerio C, Saito T, Saido TC, De Strooper B
Nature. 2017

Loss of Phospholipase D3 (PLD3) function has been proposed to increase the risk for Alzheimer’s disease by affecting the processing of the Aβ precursor protein APP. However, researchers at the De Strooper lab have found that PLD3 is not relevant for APP metabolism in wild-type mice or in a mouse model of Alzheimer’s disease pathology. They demonstrated that the PLD3 protein is localized in the lysosomal system and affects its morphology, indicating that PLD3 may be involved in the pathophysiology of Alzheimer’s disease by exacerbating impairments of the endosomal–lysosomal system.

 

   

A novel kindred with inherited STAT2 deficiency and severe viral illness 
Moens L, Van Eyck L, Jochmans D, Mitera T, Frans G, Bossuyt X, Matthys P, Neyts J, Ciancanelli M, Zhang SY, Gijsbers R, Casanova JL, Boisson-Dupuis S, Meyts I, Liston A
Journal of Allergy and Clinical Immunology. 2017

A team of scientists led by Adrian Liston and Isabelle Meyts (UZ Leuven–KU Leuven) were able to characterize a new genetic immunodeficiency resulting from a mutation in a gene named STAT2. This mutation causes patients to be extremely vulnerable to normally mild childhood illnesses such as rotavirus and enterovirus.

 

   

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease
Benoy V, Vanden Berghe P, Jarpe M, Van Damme P, Robberecht W, Van Den Bosch L
Neurotherapeutics. 2016

This paper reports on three different selective HDAC6 inhibitors, which were able to increase innervation of the neuromuscular junctions in the gastrocnemius muscle and improve motor and sensory nerve conduction. These results may speed up the translation of pharmacological inhibition of HDAC6 into a therapy against axonal Charcot-Marie-Tooth disease (CMT2).

   

Membrane defects and genetic redundancy: Are we at a turning point for DYT1 dystonia?
Cascalho A, Jacquemyn J, Goodchild RE
Mov. Disord. 2016

A review of recent major advances toward understanding the molecular, cellular, and neurobiological pathologies of DYT1/TOR1A dystonia that can hopefully be exploited for new approaches to treat this disease.

   

De novo design of a biologically active amyloid
Gallardo R, Ramakers M, De Smet F, Claes F, Khodaparast L, Khodaparast L, Couceiro JR, Langenberg T, Siemons M, Nyström S, Young LJ, Laine RF, Young L, Radaelli E, Benilova I, Kumar M, Staes A, Desager M, Beerens M, Vandervoort P, Luttun A, Gevaert K, Bormans G, Dewerchin M, Van Eldere J, Carmeliet P, Vande Velde G, Verfaillie C, Kaminski CF, De Strooper B, Hammarström P, Nilsson KP, Serpell L, Schymkowitz J, Rousseau F
Science. 2016 Nov 11;354(6313)

The Switch Laboratory has revealed a new designer molecule that inhibits a well-validated cancer driver through the mechanism of amyloid formation. This work demonstrates that amyloid structures can be used to rationally develop a novel class of biotechnological molecules that are able to fight a wide array of diseases.

   

Skywalker-TBC1D24 has a lipid-binding pocket mutated in epilepsy and required for synaptic function
Fischer B, Lüthy K, Paesmans J, De Koninck C, Maes I, Swerts J, Kuenen S, Uytterhoeven V, Verstreken P, Versées W
Nat Struct Mol Biol. 23,965–973 

The Verstreken and Versées labs collaborated to solve the crystal structure of the TBC domain of the Drosophila ortholog Skywalker, revealing an unanticipated cationic pocket conserved among TBC1D24 homologs. Mutations in TBC1D24 cause severe epilepsy and DOORS syndrome, and were found to affect the phosphoinositide-binding pocket and inhibit lipid binding.

 


 

Share on FacebookTweet about this on TwitterShare on LinkedIn